Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Anne Hagey

AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ma T, Fuld AD, Rigas JR, Hagey AE, Gordon GB, Dmitrovsky E, Dragnev KH. A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients. Chemotherapy. 2012; 58(4):321-9. PMID: 23147218.
      View in: PubMed
    2. Frugé E, Lakoski JM, Luban N, Lipton JM, Poplack DG, Hagey A, Felgenhauer J, Hilden J, Margolin J, Vaiselbuh SR, Sakamoto KM. Increasing diversity in pediatric hematology/oncology. Pediatr Blood Cancer. 2011 Jul 15; 57(1):147-52. PMID: 21284078.
      View in: PubMed
    3. Bedikian AY, Silverman JA, Papadopoulos NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsi J, Davies M, Hwu P. Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol. 2011 Aug; 51(8):1205-12. PMID: 20978276.
      View in: PubMed
    4. Mauer AM, Cohen EE, Ma PC, Kozloff MF, Schwartzberg L, Coates AI, Qian J, Hagey AE, Gordon GB. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun; 3(6):631-6. PMID: 18520803.
      View in: PubMed
    5. Fox E, Maris JM, Widemann BC, Goodspeed W, Goodwin A, Kromplewski M, Fouts ME, Medina D, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res. 2008 Feb 15; 14(4):1111-5. PMID: 18281544.
      View in: PubMed
    6. Fox E, Maris JM, Widemann BC, Meek K, Goodwin A, Goodspeed W, Kromplewski M, Fouts ME, Medina D, Cho SY, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res. 2006 Aug 15; 12(16):4882-7. PMID: 16914576.
      View in: PubMed
    7. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res. 2006 May 01; 12(9):2834-40. PMID: 16675578.
      View in: PubMed
    8. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15; 11(18):6615-24. PMID: 16166440.
      View in: PubMed
    9. Mauer AM, Szeto L, Belt RJ, Schwartzberg LS, Hagey A, Coates AI, Meek KA, Cernohous P, Gordon GB. Preliminary results of a phase 2 study of ABT-751 in patients (pts) with taxane-refractory non-small cell lung carcinoma (NSCLC). J Clin Oncol. 2005 Jun; 23(16_suppl):7137. PMID: 27944957.
      View in: PubMed
    10. Benson AB, Kindler HL, Jodrell D, Hagey A, Coates AI, Meek KA, Cernohous P, Gordon GB. Phase 2 study of ABT-751 in patients with refractory metastatic colorectal carcinoma (CRC). J Clin Oncol. 2005 Jun; 23(16_suppl):3537. PMID: 27944407.
      View in: PubMed
    11. Washington DK, Storniolo AM, Saleh M, Tan-Chiu E, Hagey A, Medina DM, Meek KA, Cernohous P, Gordon GB. Phase 2 results of ABT-751 in subjects with taxane-refractory breast cancer: Interim analysis. J Clin Oncol. 2005 Jun; 23(16_suppl):724. PMID: 27945680.
      View in: PubMed
    12. Fox E, Adamson PC, Hagey A, Widemann BC, Maris JM, Cohn SL, Cai Y, Medina DM, Meek KA, Balis FM. Phase I trial of oral ABT-751 in pediatric patients: Preliminary evidence of activity in neuroblastoma (NBL). J Clin Oncol. 2005 Jun; 23(16_suppl):8527. PMID: 27944619.
      View in: PubMed
    13. Hagey AE, Figlin RA, Moldawer N, Sosman JA, Chi KN, Medina DM, Meek KA, Cernohous P, Gordon GB. Preliminary phase 2 results of ABT-751 in subjects with advanced renal cell carcinoma (RCC). J Clin Oncol. 2005 Jun; 23(16_suppl):4603. PMID: 27946968.
      View in: PubMed
    Hagey's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Physical Neighbors Expand Description
    _